



Interest and intention to use long-acting injectable PrEP for HIV (LA-PrEP) among MSM in the Netherlands (NL) – results from the PROTECT Survey

Authors: Kolstee, J1; Wang, H1; Zimmerman, H1; Adriaque Lozano, A 1; Schroeder, M2; Appiah, A 2; Brown, C 3; Jonas, KJ1 Affiliations: 1 Department of Work and Social Psychology, Maastricht University, Maastricht, The Netherlands; 2ViiV Healthcare Ltd, Brentford, UK; 3ViiV Healthcare Ltd, Durham, NC USA

BACKGROUND

Long-acting injectable PrEP for HIV (LA-PrEP), Cabotegravir, has been approved for use in Europe. Understanding who demonstrates interest and intent to use LA-PrEP is critical to help reduce new HIV infections. In the Netherlands men-who-have-sex-withmen (MSM) must be engaged with new HIV prevention options.

KEY FINDING 1: Interest in LA PrEP is high among MSM in NL, especially among current oral PrEP users




The Understanding Pre-exposure pRophylaxis mOdalities for HIV prevenTion in the European CommuniTies (PROTECT) Survey was a cross sectional online survey that collected data in 20 European countries.

In the Netherlands, data collection occurred from October 2023 to March 2024 among MSM greater than 18 years old. Data from MSM participants residing in the Netherlands were analysed to produce descriptive data and to undertake multivariate regression analyses to determine factors associated with intention to use LA-PrEP. A total of 1237 surveys were completed by MSM and included in this analysis. A separate analysis will show the results of trans* people in Europe

PrEP Use History (N=1237)

KEY FINDING 2: Intention to use LA PrEP is high among MSM in NL, especially among current oral PrEP users



KEY FINDING 3: Intention to use LA-PrEP among all participants was associated with greater numbers of sex partners and greater worry about HIV and perceived risk of acquiring HIV. Less frequent STI testing, concerns about post injection pain and perceived side effects were negatively associated.



KEY MESSAGES

> In the Netherlands:

- Current oral PrEP users are more interested in LA-PrEP than PrEP naïve or discontinued users
- Having many sex partners and having worry about HIV is associated with the intent to use LA PrEP among MSM

MSM who are worried about injection pain and perceived side effects of PrEP are less likely to intend to use LA PrEP

	-		e Confidence	e
Variable (Green = significant positive association,	odds	interval	interval	
Blue = significant negative association)	ratio	low	high	P-value
Chemsex	1.356	0.948	1.957	0.099
# sex partners past 6 months (1)	0.911	0.378	2.214	0.836
# sex partners past 6 months (101-150)	1.458	0.368	6.647	0.604
# sex partners past 6 months (11-50)	2.881	1.291	6.504	0.001
# sex partners past 6 months (150+)	3.461	1.455	8.378	0.005
# sex partners past 6 months (2-10)	1.672	0.775	3.643	0.190
# sex partners past 6 months (51-100)	2.231	0.812	6.339	0.124
STI testing freq – Every six months	0.841	0.553	1.284	0.418
STI testing freq – Less than once per year	0.566	0.329	0.974	0.039
STI testing freq – Never	0.856	0.459	1.604	0.625
STI testing freq – Once per year	0.833	0.491	1.427	0.502
Perceived worry about HIV	1.448	1.178	1.798	0.001
Perceived risk of acquiring HIV	1.270	1.065	1.518	0.008
Concerns about post injection pain	0.670	0.601	0.746	<0.001
Perceived side effects of LA PrEP	0.858	0.756	0.971	0.016
Former PrEP use	1.013	0.546	1.950	0.968
Naïve PrEP use	0.751	0.490	1.148	0.186

KEY FINDING 4: Intention to use LA-PrEP among current oral PrEP users was associated with greater perceived risk of acquiring HIV. Not having a migrant background, living in a medium sized city, concerns about post injection pain and perceived side effects were negatively associated.



	Adjusted	ljusted Confidence Confidence				
Variable (Green = significant positive association,	odds	interval	interval			
Blue = significant negative association)	ratio	low	high	P-value		
Migrant Status (Local)	0.536	0.288	0.960	0.042		
Migrant Status (Second Generation migrant)	0.547	0.235	1.300	0.164		
Resident of - A big city or town (500,000-	0.572	0.229	1.287	0.200		
999,999 people)						
Resident of - A medium-sized city or town	0.383	0.152	0.870	0.029		
(100,000-499,999 people)						
Resident of - A small city or town (10,000-	0.789	0.283	2.069	0.637		
99,999 people)						
Resident of - A village / the countryside (less	0.367	0.123	1.048	0.065		
than 10,000 people)						
Perceived worry about HIV	1.316	0.936	1.897	0.127		
Perceived risk of acquiring HIV	1.659	1.227	2.283	0.001		
Concerns about post injection pain	0.684	0.580	0.806	<0.001		
Perceived side effects of LA PrEP	0.799	0.657	0.967	0.023		
PrEP regimen (Mixed use)	1.013	0.516	2.078	0.970		
PrEP regimen (On-demand)	0.865	0.542	1.378	0.541		

Contact Maastricht University

UM postal address P.O. Box 616 6200 MD Maastricht The Netherlands UM visiting address Universiteitssingel 40 6229 ER Maastricht The Netherlands To learn more about PROTECT follow the QR code



PROTECT was partly funded by ViiV Healthcare